| Title |
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, January 2014
|
| DOI | 10.1002/14651858.cd007115.pub3 |
| Pubmed ID | |
| Authors |
Michael PT Lunn, Richard AC Hughes, Philip J Wiffen |
| Abstract |
Duloxetine is a balanced serotonin and noradrenaline reuptake inhibitor licensed for the treatment of major depressive disorders, urinary stress incontinence and the management of neuropathic pain associated with diabetic peripheral neuropathy. A number of trials have been conducted to investigate the use of duloxetine in neuropathic and nociceptive painful conditions. This is the first update of a review first published in 2010. |
X Demographics
The data shown below were collected from the profiles of 81 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 21 | 26% |
| United Kingdom | 6 | 7% |
| Chile | 5 | 6% |
| Canada | 5 | 6% |
| United States | 4 | 5% |
| Mexico | 3 | 4% |
| Australia | 2 | 2% |
| Ecuador | 1 | 1% |
| Colombia | 1 | 1% |
| Other | 5 | 6% |
| Unknown | 28 | 35% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 71 | 88% |
| Practitioners (doctors, other healthcare professionals) | 8 | 10% |
| Science communicators (journalists, bloggers, editors) | 1 | 1% |
| Scientists | 1 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 723 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | <1% |
| Switzerland | 1 | <1% |
| Brazil | 1 | <1% |
| Canada | 1 | <1% |
| Denmark | 1 | <1% |
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 714 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 99 | 14% |
| Student > Bachelor | 85 | 12% |
| Researcher | 81 | 11% |
| Student > Postgraduate | 57 | 8% |
| Other | 56 | 8% |
| Other | 145 | 20% |
| Unknown | 200 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 247 | 34% |
| Nursing and Health Professions | 66 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 36 | 5% |
| Psychology | 34 | 5% |
| Neuroscience | 25 | 3% |
| Other | 90 | 12% |
| Unknown | 225 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 112. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 September 2023.
All research outputs
#383,801
of 25,853,983 outputs
Outputs from Cochrane database of systematic reviews
#631
of 13,147 outputs
Outputs of similar age
#3,538
of 320,534 outputs
Outputs of similar age from Cochrane database of systematic reviews
#12
of 242 outputs
Altmetric has tracked 25,853,983 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,147 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.2. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,534 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 242 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.